Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Seckinger, Hillengass, Emde, Beck, Kimmich, Dittrich, Hundemer, Jauch, Hegenbart, Raab, Ho, Schönland and Hose.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Association with survival. Impact of low vs. high CD38 expression according to gene expression profiling on (A) time to progression in asymptomatic myeloma patients, (B1) event-free and overall survival for our patient cohort treated with high-dose chemotherapy followed by autologous stem cell transplantation, including (B2) validation for patients treated within the total therapy 2 or 3 protocol, respectively, (C) overall survival of patients with relapsed/refractory myeloma, as well as (D) hematologic event-free and overall survival for patients with AL-amyloidosis. Patients with “high” and “low” CD38 expression in microarray data were delineated using maximally selected rank statistics with maxstat thresholds calculated for each entity: 13.34 (AMM), 11.64 (MM), 11.53 (MMR), and 13.15/12.95 (AL EFS/OS), respectively.

Association with survival. Impact of low vs. high CD38 expression according to gene expression profiling on (A) time to progression in asymptomatic myeloma patients, (B1) event-free and overall survival for our patient cohort treated with high-dose chemotherapy followed by autologous stem cell transplantation, including (B2) validation for patients treated within the total therapy 2 or 3 protocol, respectively, (C) overall survival of patients with relapsed/refractory myeloma, as well as (D) hematologic event-free and overall survival for patients with AL-amyloidosis. Patients with “high” and “low” CD38 expression in microarray data were delineated using maximally selected rank statistics with maxstat thresholds calculated for each entity: 13.34 (AMM), 11.64 (MM), 11.53 (MMR), and 13.15/12.95 (AL EFS/OS), respectively.